Cyclodextrin-Stabilized Sulforaphene for Mitochondrial Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for mitochondrial disorders are inadequate due to the instability and limited bioavailability of sulforaphene, a compound found in radish seeds, which loses efficacy shortly after isolation.
Innovation Solution
Stabilization of sulforaphene through chemical modification or complexation with agents like hydroxypropyl-beta-cyclodextrin to create a pharmaceutical or nutraceutical composition that prolongs its bioactivity and enhances its ability to treat mitochondrial disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If sulforaphene is isolated from radish seeds for therapeutic use, then it can be administered to treat mitochondrial disorders, but it loses efficacy and stability shortly after isolation
Solution Approach 1:
The patent uses cyclodextrins as intermediary molecules to complex with sulforaphene, creating a stable host-guest complex. The cyclodextrin acts as a mediator that protects sulforaphene from degradation while maintaining its therapeutic activity, resolving the contradiction between stability and efficacy.
Solution Approach 2:
The invention creates a composite pharmaceutical composition consisting of sulforaphene complexed with cyclodextrin. This composite material combines the therapeutic properties of sulforaphene with the stabilizing properties of cyclodextrin, achieving both reliability and stability simultaneously.
2Reliability
If sulforaphene is used to treat mitochondrial disorders, then it shows therapeutic potential, but its bioavailability is limited
Solution Approach 1:
Cyclodextrins serve as solubilizing agents that enhance the bioavailability of sulforaphene by forming soluble complexes. This intermediary approach allows the poorly bioavailable sulforaphene to be delivered effectively to target tissues while maintaining its therapeutic potential.
3Reliability
If stable sulforaphene composition is administered, then cellular ATP production increases and mitochondrial function improves, but the composition complexity increases
Solution Approach 1:
The patent employs cyclodextrin-sulforaphene complexes as a relatively simple composite material system. While this does increase composition complexity compared to pure sulforaphene, the complexity is manageable and justified by the significant improvement in mitochondrial function and therapeutic reliability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The stabilized sulforaphene composition increases cellular ATP production, improving mitochondrial function and treating conditions such as mitochondrial myopathy, essential tremor, and skin disorders by maintaining bioactivity over time.
Implementation Method 1
the sulforaphene may be stabilized by the presence of one or more solubilizing agents in the pharmaceutical or nutraceutical composition. In one embodiment, the stabilizing agent is a cyclodextrin
Implementation Method 2
mitochondria generate ATP from adenosine diphosphate (ADP) during cellular respiration by transferring electrons from NADH or FADH2 to O2 through electron carriers, a process known as the electron transport train. The energy released when electrons are passed from higher-energy NADH or FADH2 to the lower-energy O2 is required to phosphorylate ADP and generate ATP
Data Source
AI summary
The present disclosure provides pharmaceutical and nutraceutical compositions and methods for the treatment of mitochondrial disorders. The pharmaceutical or nutraceutical compositions include a stabilized sulforaphene, such as sulforaphene-cyclodextrin complex, that increases the efficacy, biological activity and stability of isolated sulforaphene. The present disclosure also includes the use of stabilized sulforaphene as an effective therapeutic agent for the treatment of mitochondrial disorders, such as mitochondrial myopathy.